Standard BioTools Inc. Deferred Revenue
Standard BioTools Inc. (LAB) had Deferred Revenue of $10.76 million as of 2018-06-30, per its 10-Q filed 2018-08-08.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2018-08-08
- 2018-06-30: Deferred Revenue, Current $10.76M.
- 2018-03-31: Deferred Revenue, Current $10.64M.
- 2017-12-31: Deferred Revenue, Current $10.24M.
- 2017-09-30: Deferred Revenue, Current $9.88M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2018-06-30 | $10.76M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $10.64M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $10.24M 10-Q · filed 2018-08-08 |
| 2017-09-30 | $9.88M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $9.10M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $9.90M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $9.16M 10-K · filed 2018-03-08 |
| 2016-09-30 | $9.72M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $9.03M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $9.10M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $9.42M 10-K · filed 2017-03-03 |
| 2015-09-30 | $8.18M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $7.55M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $7.35M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $6.93M 10-K · filed 2016-02-29 |
| 2014-09-30 | $6.63M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $5.87M 10-Q · filed 2014-08-04 |
| 2014-03-31 | $5.33M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $2.72M 10-K · filed 2015-02-26 |
| 2013-09-30 | $2.81M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $2.22M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $1.93M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $1.89M 10-K · filed 2014-03-12 |
| 2012-09-30 | $2.13M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $1.73M 10-Q · filed 2012-08-14 |
| 2012-03-31 | $1.53M 10-Q · filed 2012-05-15 |
| 2011-12-31 | $2.01M 10-K · filed 2013-03-12 |
| 2011-09-30 | $1.82M 10-Q · filed 2011-11-14 |
| 2011-06-30 | $1.79M 10-Q · filed 2011-08-09 |
| 2010-12-31 | $1.34M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |